ArticleFrontiers in medicine2026

Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort.

Kerstin Wimmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.